Nonprescription naloxone and syringe sales in the midst of opioid overdose and hepatitis C virus epidemics: Massachusetts, 2015

Journal of the American Pharmacists Association

Volumn 57, Issue 2, 2017, Pages S34-S44

  Stopka, Thomas J ^a   Donahue, Ashley ^a   Hutcheson, Marguerite ^a   Green, Traci C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NALOXONE; NON PRESCRIPTION DRUG; OPIATE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL PHARMACY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG OVERDOSE; EPIDEMIC; GEOGRAPHIC INFORMATION SYSTEM; HARM REDUCTION; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH SERVICE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MASSACHUSETTS; OUTCOME ASSESSMENT; PERSONAL EXPERIENCE; PRESCRIPTION; PREVALENCE; TELEPHONE INTERVIEW; VIRUS TRANSMISSION; HEALTH CARE DELIVERY; HEALTH CARE SURVEY; ORGANIZATION AND MANAGEMENT; PHARMACIST; PHARMACY; PROFESSIONAL STANDARD; STATISTICS AND NUMERICAL DATA; SUPPLY AND DISTRIBUTION; SYRINGE;

ANALGESICS, OPIOID; COMMUNITY PHARMACY SERVICES; CROSS-SECTIONAL STUDIES; DRUG OVERDOSE; HEALTH CARE SURVEYS; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HUMANS; MASSACHUSETTS; NALOXONE; NARCOTIC ANTAGONISTS; NONPRESCRIPTION DRUGS; PHARMACISTS; PROFESSIONAL ROLE; SYRINGES;

EID: 85026579820     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1016/j.japh.2016.12.077     Document Type: Article

References (63)

1. Calcaterra, S., Glanz, J., Binswanger, I.A., National trends in pharmaceutical opioid related overdose deaths compared to other substance related overdose deaths: 1999-2009. Drug Alcohol Depend 131:3 (2013), 263–270.
2. Centers for Disease Control and Prevention. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999-2008. MMWR Morb Mortal Wkly Rep 60:43 (2011), 1487–1492.
3. Massachusetts Department of Public Health, Data Brief: Fatal Opioid-related Overdoses among Massachusetts Residents. November 2016 Available at: http://www.mass.gov/eohhs/docs/dph/stop-addiction/current-statistics/data-brief-overdose-deaths-nov-2016-ma-residents.pdf Accessed December 19, 2016.
4. Detonating a viral time bomb–the hepatitis C pandemic. Lancet, 381(9862), 2013, 178.
5. Mohd Hanafiah, K., Groeger, J., Flaxman, A.D., Wiersma, S.T., Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 57:4 (2013), 1333–1342.
6. Zibbell, J.E., Hart-Malloy, R., Barry, J., Fan, L., Flanigan, C., Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics. Am J Public Health 104:11 (2014), 2226–2232.
7. Valdiserri, R., Khalsa, J., Dan, C., et al. Confronting the emerging epidemic of HCV infection among young injection drug users. Am J Public Health 104:5 (2014), 816–821.
8. Bureau of Infectious Diseases, MDPH, Shifting epidemics: HIV and hepatitis C infection among injection drug users in Massachusetts. 2012 Available at: http://www.mass.gov/eohhs/docs/dph/aids/shifting-epidemics-report.pdf Accessed November 15, 2016.
9. Suryaprasad, A.G., White, J.Z., Xu, F., et al. Emerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012. Clin Infect Dis 59:10 (2014), 1411–1419.
10. Wolfe, D., Luhmann, N., Harris, M., et al. Human rights and access to hepatitis C treatment for people who inject drugs. Int J Drug Policy 26:11 (2015), 1072–1080.
11. Hammett, T.M., Phan, S., Gaggin, J., et al. Pharmacies as providers of expanded health services for people who inject drugs: a review of laws, policies, and barriers in six countries. BMC Health Serv Res, 14, 2014, 261.
12. Watson, T., Hughes, C., Pharmacists and harm reduction: a review of current practices and attitudes. Can Pharm J (Ott) 145:3 (2012), 124–127.e122.
13. Eades, C.E., Ferguson, J.S., O'Carroll, R.E., Public health in community pharmacy: a systematic review of pharmacist and consumer views. BMC Public Health, 11, 2011, 582.
14. Fuller, C., Galea, S., Caceres, W., Blaney, S., Sisco, S., Vlahov, D., Multilevel community-based intervention to increase access to sterile syringes among injection drug users through pharmacy sales in New York City. Am J Public Health 97:1 (2007), 117–124.
15. Deibert, R., Goldbaum, G., Parker, T., et al. Increased access to unrestricted pharmacy sales of syringes in Seattle-King County, Washington: structural and individual-level changes, 1996 versus 2003. Am J Public Health 96:8 (2006), 1347–1353.
16. Valleroy, L., Weinstein, B., Jones, T., Groseclose, S., Rolfs, R., Kassler, W., Impact of increased legal access to needles and syringes on community pharmacies' needle and syringe sales–Connecticut, 1992-1993. J Acquir Immune Defic Syndr Hum Retrovirol 10:1 (1995), 73–81.
17. Burris, S., Welsh, J., Ng, M., Li, M., Ditzler, A., State syringe and drug possession laws potentially influencing safe syringe disposal by injection drug users. J Am Pharm Assoc (Wash) 42:6 Suppl 2 (2002), S94–98.
18. Singer, M., Baer, H., Scott, G., Horowitz, S., Weinstein, B., Pharmacy access to syringes among injecting drug users: follow-up findings from Hartford, Connecticut. Public Health Rep 113:suppl 1 (1998), 81–89.
19. Junge, B., Vlahov, D., Riley, E., Huettner, S., Brown, M., Beilenson, P., Pharmacy access to sterile syringes for injection drug users: attitudes of participants in a syringe exchange program. J Am Pharm Assoc (Wash) 39:1 (1999), 17–22.
20. Compton, W., Horton, J., Cottler, L., et al. A multistate trial of pharmacy syringe purchase. J Urban Health 81:4 (2004), 661–670.
21. Fuller, C., Ahern, J., Vadnai, L., et al. Impact of increased syringe access: preliminary findings on injection drug user syringe source, disposal, and pharmacy sales in Harlem, New York. J Am Pharm Assoc (Wash) 42:6 suppl 2 (2002), S77–82.
22. Bluthenthal, R., Kral, A., Gee, L., Erringer, E., Edlin, B., The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS 14:5 (2000), 605–611.
23. Hurley, S., Jolley, D., Kaldor, J., Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet 349:9068 (1997), 1797–1800.
24. MacDonald, M., Law, M., Kaldor, J., Hales, J., Dore, G.J., Effectiveness of needle and syringe programs for preventing HIV transmission. Int J Drug Policy 14:5-6 (2003), 353–357.
25. Stopka, T., Garfein, R., Ross, A., Truax, S., Increasing syringe access and HIV prevention in California: findings from a survey of local health jurisdiction key personnel. J Urban Health 84:1 (2007), 116–125.
26. Pouget, E., Deren, S., Fuller, C., et al. Receptive syringe sharing among injection drug users in Harlem and the Bronx during the New York State Expanded Syringe Access Demonstration Program. J Acquir Immune Defic Syndr 39:4 (2005), 471–477.
27. Wodak, A., Cooney, A., Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse 41:6-7 (2006), 777–813.
28. Neaigus, A., Zhao, M., Gyarmathy, V., Cisek, L., Friedman, S., Baxter, R., Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal. J Urban Health 85:3 (2008), 309–322.
29. Friedman, S., Perlis, T., Des Jarlais, D., Laws prohibiting over-the-counter syringe sales to injection drug users: relations to population density, HIV prevalence, and HIV incidence. Am J Public Health 91:5 (2001), 791–793.
30. Holmberg, S.D., The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health 86:5 (1996), 642–654.
31. Lewis, C.F., Rivera, A.V., Crawford, N.D., DeCuir, J., Amesty, S., Pharmacy-randomized intervention delivering HIV prevention services during the syringe sale to people who inject drugs in New York City. Drug Alcohol Depend 153 (2015), 72–77.
32. Jones, T., Coffin, P., Preventing blood-borne infections through pharmacy syringe sales and safe community syringe disposal. J Am Pharm Assoc (Wash) 42:6 suppl 2 (2002), S6–9.
33. Pollini, R.A., Rudolph, A.E., Case, P., Nonprescription syringe sales: a missed opportunity for HIV prevention in California. J Am Pharm Assoc (2003) 55:1 (2015), 31–40.
34. Reich, W., Compton, W., Horton, J., et al. Injection drug users report good access to pharmacy sale of syringes. J Am Pharm Assoc (Wash) 42:6 suppl 2 (2002), S68–72.
35. Zaller, N.D., Yokell, M.A., Nayak, S.M., Fu, J.J., Bazazi, A.R., Rich, J.D., Syringe acquisition experiences and attitudes among injection drug users undergoing short-term opioid detoxification in Massachusetts and Rhode Island. J Urban Health 89:4 (2012), 659–670.
36. Lutnick, A., Case, P., Kral, A.H., Injection drug users’ perspectives on placing HIV prevention and other clinical services in pharmacy settings. J Urban Health 89:2 (2012), 354–364.
37. Zaller, N., Jeronimo, A., Bratberg, J., Case, P., Rich, J.D., Pharmacist and pharmacy staff experiences with non-prescription (NP) sale of syringes and attitudes toward providing HIV prevention services for injection drug users (IDUs) in Providence, RI. J Urban Health 87:6 (2010), 942–953.
38. Cooper, E.N., Dodson, C., Stopka, T.J., Riley, E.D., Garfein, R.S., Bluthenthal, R.N., Pharmacy participation in non-prescription syringe sales in Los Angeles and San Francisco counties, 2007. J Urban Health 87:4 (2010), 543–552.
39. Green, T.C., Dauria, E.F., Bratberg, J., Davis, C.S., Walley, A.Y., Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduct J, 12, 2015, 25.
40. U.S. Food and Drug Administration. Exploring Naloxone Uptake and Use: A Public Meeting. Silver Spring, MD; July 1-2, 2015.
41. Zaller, N.D., Yokell, M.A., Green, T.C., Gaggin, J., Case, P., The feasibility of pharmacy-based naloxone distribution interventions: a qualitative study with injection drug users and pharmacy staff in Rhode Island. Subst Use Misuse 48:8 (2013), 590–599.
42. Davis, C.S., Walley, A.Y., Bridger, C.M., Lessons learned from the expansion of naloxone access in Massachusetts and North Carolina. J Law Med Ethics 43:suppl 1 (2015), 19–22.
43. Moore, D.A., Carpenter, T.E., Spatial analytical methods and geographic information systems: use in health research and epidemiology. Epidemiol Rev 21:2 (1999), 143–161.
44. Cooper, H., Bossak, B., Tempalski, B., Des Jarlais, D., Friedman, S., Geographic approaches to quantifying the risk environment: drug-related law enforcement and access to syringe exchange programmes. Int J Drug Policy 20:3 (2009), 217–226.
45. Cooper, H.L., Bossak, B.H., Tempalski, B., Friedman, S.R., Des Jarlais, D.C., Temporal trends in spatial access to pharmacies that sell over-the-counter syringes in New York City health districts: relationship to local racial/ethnic composition and need. J Urban Health 86:6 (2009), 929–945.
46. Meyers, D.J., Hood, M.E., Stopka, T.J., HIV and hepatitis C mortality in Massachusetts, 2002-2011: spatial cluster and trend analysis of HIV and HCV using multiple cause of death. PLoS One, 9(12), 2014, e114822.
47. Stopka, T.J., Krawczyk, C., Gradziel, P., Geraghty, E.M., Use of spatial epidemiology and hot spot analysis to target women eligible for prenatal women, infants, and children services. Am J Public Health 104:suppl 1 (2014), S183–189.
48. Harris, P.A., Taylor, R., Thielke, R., Payne, J., Gonzalez, N., Conde, J.G., Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42:2 (2009), 377–381.
49. United States Census Bureau, American FactFinder. Available at: http://factfinder.census.gov Accessed August 3, 2011.
50. Geoservices TAMU, Geocoding Services. 2016 Available at: http://geoservices.tamu.edu/Services/Geocode/ Accessed September 3, 2016.
51. Wakeman, S.E., Green, T.C., Rich, J.D., From documenting death to comprehensive care: applying lessons from the HIV/AIDS epidemic to addiction. Am J Med 127:6 (2014), 465–466.
52. Walley, A.Y., HIV prevention and treatment strategies can help address the overdose crisis. Prev Med 80 (2015), 37–40.
53. Stopka, T.J., Lutnick, A., Wenger, L.D., Deriemer, K., Geraghty, E.M., Kral, A.H., Demographic, risk, and spatial factors associated with over-the-counter syringe purchase among injection drug users. Am J Epidemiol 176:1 (2012), 14–23.
54. Garfein R, Stopka T, Pavlinac P, et al. Three Years into Legalization of Over-the-Counter (OTC) Syringe Sales in California (SB1159). Where are we now? Oral presentation at the American Public Health Association 136st Annual Meeting, San Diego, CA; 2008.
55. Garfein, R.S., Stopka, T.J., Pavlinac, P.B., et al. Three years after legalization of nonprescription pharmacy syringe sales in California: where are we now?. J Urban Health 87:4 (2010), 576–585.
56. Reich, W., Compton, W.M., Horton, J.C., et al. Pharmacist ambivalence about sale of syringes to injection drug users. J Am Pharm Assoc (Wash) 42:6 suppl 2 (2002), S52–57.
57. Riley, E., Safaeian, M., Strathdee, S., et al. Comparing new participants of a mobile versus a pharmacy-based needle exchange program. J Acquir Immune Defic Syndr 24:1 (2000), 57–61.
58. Torre, C., Lucas, R., Barros, H., Syringe exchange in community pharmacies–The Portuguese experience. Int J Drug Policy 21:6 (2010), 514–517.
59. Jaffray, M., Matheson, C., Bond, C.M., et al. Does training in motivational interviewing for community pharmacists improve outcomes for methadone patients? A cluster randomised controlled trial. Int J Pharm Pract 22:1 (2014), 4–12.
60. Ahamad, K., Hayashi, K., Nguyen, P., et al. Effect of low-threshold methadone maintenance therapy for people who inject drugs on HIV incidence in Vancouver, BC, Canada: an observational cohort study. Lancet HIV 2:10 (2015), e445–450.
61. Chaar, B.B., Wang, H., Day, C.A., Hanrahan, J.R., Winstock, A.R., Fois, R., Factors influencing pharmacy services in opioid substitution treatment. Drug Alcohol Rev 32:4 (2013), 426–434.
62. Gupta, R., Shah, N.D., Ross, J.S., The rising price of naloxone—Risks to efforts to stem overdose deaths. N Engl J Med 375:23 (2016), 2213–2215.
63. Stopka, T.J., Singer, M., Teng, W., Horton, J., Compton, W., Pharmacy access to over-the-counter syringes in Connecticut: implications for HIV and hepatitis prevention among injection drug users. AIDS Public Policy J 17:4 (2002), 118–129.